Welcome to the newest member of the Colon Cancer Alliance Board of Directors, Dr. Johanna Bendell! Dr. Bendell is currently the Director of GI Cancer Research and Associate Director of Drug Development at Sarah Cannon Research Institute in Nashville, TN. She is board certified in internal medicine and medical oncology and received her undergraduate and medical degrees from the University of Chicago.
[caption id="attachment_914" align="alignright" width="320"]
Dr. Bendell completed her internship and residency in the Department of Internal Medicine at Brigham and Women’s Hospital in Boston, MA, as well as a fellowship in adult oncology at Boston’s Dana-Farber Cancer Institute. After finishing her training, she served as assistant of medicine at Massachusetts General Hospital and an instructor in medicine at Harvard Medical School.
After teaching at Harvard, Dr. Bendell was an assistant professor at Duke University specializing in gastrointestinal cancers and phase I research, In 2008, she headed to Nashville to join the Sarah Cannon Research Institute team. At Sarah Cannon, Dr. Bendell leads GI Oncology research, where she designs the trial menu across all GI tumor types for the Sarah Cannon research network. She also focuses on early drug development of primarily targeted agents. Dr. Bendell has published in multiple journals including the Journal of Clinical Oncology, Cancer and The Lancet.
And did we mention she participates in the Nashville Undy 5000 5K? We’re thrilled to welcome such a knowledgeable and dynamic member to the Colon Cancer Alliance family!
[caption id="attachment_915" align="alignleft" width="343"]
In Dr. Bendell’s words: “I’m so excited to join this influential organization whose purpose is to improve the lives of patients with colorectal cancer and increase public awareness of this difficult disease, so that we might find a way to eventually eradicate it.”
Be sure to stop by our Facebook page and give Dr. Bendell a warm welcome!